CORT CORCEPT THERAPEUTICS INC

Nasdaq Pharmaceutical Preparations DE CIK: 0001088856
AI RATING
SELL
72% Confidence

Investment Thesis

Revenue is growing at 12.8% YoY with healthy 51.2% gross margins, but the company is deeply unprofitable with operating losses of $49.6M and negative free cash flow of $17.0M, indicating unsustainable cash burn despite a strong balance sheet providing runway.

Strengths

  • + Revenue growth of 12.8% YoY demonstrates market demand and business traction
  • + Strong gross margins of 51.2% show healthy core product economics
  • + Fortress balance sheet with $108.7M cash, zero debt, and 2.86x current ratio provides 6+ years of runway

Risks

  • ! Negative free cash flow of $17.0M annually is structurally unsustainable long-term
  • ! Operating margin of -30.1% shows severe inability to control operating expenses relative to revenue
  • ! EPS declining 33.3% YoY indicates worsening profitability trajectory despite revenue growth

Key Metrics to Watch

Financial Metrics

Revenue
164.9M
Net Income
-31.8M
EPS (Diluted)
$-0.30
Free Cash Flow
-17.0M
Total Assets
814.9M
Cash
108.7M

Profitability Ratios

Gross Margin 51.2%
Operating Margin -30.1%
Net Margin -19.3%
ROE -5.0%
ROA -3.9%
FCF Margin -10.3%

Balance Sheet & Liquidity

Current Ratio
2.86x
Quick Ratio
2.77x
Debt/Equity
0.00x
Debt/Assets
21.7%
Interest Coverage
-29.18x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T17:20:00.631064 | Data as of: 2026-03-31 | Powered by Claude AI